Biotech Values

[DewDiligence]

RVNC—…add to that JPM19 breakfast meeting followed by showcasing ‘ground breaking’ data, you have perfect storm for big pharma to take notice.

RVNC’s Special Investor Breakfast at JPM, which was hosted by Cowen, was plainly for the purpose of lining up institutional investors—not for discussing potential partnerships with other drug/biotech companies:

What a great meeting! Thank you Dr Dover and Dr Fabi for your insights and thank you to @cowenresearch for hosting such an amazing event with us! $rvnc#jpm2019 #jpm19 #biotechweek19 #aestheticmedicine#medaesthetics #dermatology #innovation #clinicaltrials #neuromodulation pic.twitter.com/dmMlXvnzY9

— Revance (@revance) January 9, 2019